Trouble reading this email? View it in your browser
European Federation of Pharmaceutical industries and associations
   

EFPIA Newsletter 01 July 2021

 
 
 
   

COVID-19 Vaccines: Meeting the world's need

The industry is on target to exceed 11 billion vaccine doses by the end of 2021. But rapid action is needed to tackle manufacturing bottlenecks. Watch the video here:



At present it can take between 90 to 120 days to manufacture a single batch of COVID-19 vaccine whether mRNA, viral vector or recombinant protein. Companies are working to reduce lead times as much as possible. Read more in this blog.

 
 
 
 
   

Catch up with EFPIA's recent events

 

Beating cancer: Looking ahead, learning from the past
COVID-19 has had an impact on every patient access milestone and will have a profound effect on patient outcomes if... Read more

How can COVID-19 treatments help us on the road to recovery?
While vaccination programmes continue to scale up around the world, therapeutics play a key role in saving lives, freeing... Read more

 
 
 
   

Together, we can be #StrongerThanEver in the fight against cancer

When COVID hit, it felt like the whole world stopped. But cancer didn’t stop, so neither did we. Looking at what we have learnt, by continuing to work together, we can be #StrongerThanEver in the fight against cancer. Watch our video here:



The COVID-19 pandemic has hit every aspect of cancer care, putting patients at higher risk of poor outcomes. Despite the challenges, there have been some positive features of Europe’s response to the pandemic, including the adoption of digital health and greater agility in the development and approval of innovative solutions.

Stakeholders have identified six recommendations which can make cancer care delivery more resilient to disruptions and more sustainable in the post-pandemic world. Read them here.

 
 
 
 
   

What we are reading

 

MEP: Public-private partnerships needed to face silent threat of AMR
On 01 July 2021 (Euractiv)

The silent threat of antimicrobial resistance (AMR) must be fought with investment in research and development and by... Read more

Incentives alone are not enough to cope with rare disease, report says
On 01 July 2021 (Euractiv)

A new report by a multidisciplinary group of experts bringing together researchers, academia and the pharma industry,... Read more

Nitrosamine Impurities – Understanding Risks, Overcoming Challenges
On 30 June 2021 (Technology Networks)

Giovanna Rizzetto, senior manager at the European Federation of Pharmaceutical Industries and Associations (EFPIA),... Read more